Stockscreener 앱 받기
2.87
4.01%
-0.12
시간 외 거래:
3.10
0.23
+8.01%
전일 마감가:
$2.99
열려 있는:
$2.86
하루 거래량:
817.43K
Relative Volume:
1.62
시가총액:
$643.85M
수익:
$58.17M
순이익/손실:
$-281.50M
주가수익비율:
-1.8347
EPS:
-1.5643
순현금흐름:
$-349.78M
1주 성능:
-9.18%
1개월 성능:
+15.26%
6개월 성능:
-11.96%
1년 성능:
-27.53%
1일 변동 폭
$2.83
$3.02
1주일 범위
$2.68
$3.20
52주 변동 폭
$2.215
$5.28
큐어백 Stock (CVAC) Company Profile
CVAC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
2.87 | 643.85M | 58.17M | -281.50M | -349.78M | -1.2766 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
큐어백 Stock (CVAC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-25 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-06-08 | 개시 | SVB Securities | Outperform |
| 2023-01-19 | 업그레이드 | UBS | Neutral → Buy |
| 2023-01-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-01-21 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-01-18 | 개시 | JMP Securities | Mkt Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Hold |
| 2021-06-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-04-26 | 재개 | Credit Suisse | Underperform |
| 2021-04-26 | 개시 | Guggenheim | Neutral |
| 2020-12-10 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2020-09-08 | 개시 | BofA Securities | Buy |
| 2020-09-08 | 개시 | Credit Suisse | Neutral |
| 2020-09-08 | 개시 | Jefferies | Hold |
모두보기
큐어백 주식(CVAC)의 최신 뉴스
CureVac (NASDAQ:CVAC) Shares Gap DownShould You Sell? - MarketBeat
CureVac (NASDAQ:CVAC) Trading 4.7% HigherHere's What Happened - MarketBeat
CureVac (NASDAQ:CVAC) Shares Down 5.5%What's Next? - MarketBeat
CureVac's SWOT analysis: mRNA pioneer's stock faces oncology pipeline hurdles - Investing.com
2 Small-Cap Stocks Set to Shine in a Bull Market - Benzinga
CUREVAC : Licensing deal boosts bank account - Marketscreener.com
Point72 Asset Management L.P. Sells 1,642,723 Shares of CureVac (NASDAQ:CVAC) - MarketBeat
CUREVAC : Positive one-off overshadows pipeline dryness - Marketscreener.com
mRNA Therapeutics Market Size to Hit USD 48.65 Billion by 2032 due to Advances in Cancer Treatment and Expanding mRNA Vaccine Applications | Research by SNS Insider - GlobeNewswire Inc.
CureVac NV (XTER:5CV) 50-Day SMA : €2.62 (As of Dec. 05, 2024) - GuruFocus.com
CureVac NV (STU:5CV) 5-Day RSI : 64.31 (As of Dec. 05, 2024) - GuruFocus.com
CureVac's SWOT analysis: mRNA pioneer's stock faces pivotal phase in oncology push - Investing.com
CureVac NV (LTS:0A9E) EBITDA per Share : $0.84 (TTM As of Sep. 2024) - GuruFocus.com
CureVac NV (LTS:0A9E) Profitability Rank : 3 (As of Sep. 2024) - GuruFocus.com
CureVac NV (LTS:0A9E) 3-Year FCF Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
CureVac NV (HAM:5CV) Cyclically Adjusted FCF per Share : €0.00 (As of Sep. 2024) - GuruFocus.com
CureVac NV (WBO:CVAC) Enterprise Value : €94.9 Mil (As of Dec. 01, 2024) - GuruFocus.com
CureVac NV (HAM:5CV) Altman Z-Score : 2.46 (As of Dec. 01, 2024) - GuruFocus.com
CureVac NV (STU:5CV) 3-Year FCF Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
CureVac NV (STU:5CV) Cyclically Adjusted Revenue per Share : €0.00 (As of Sep. 2024) - GuruFocus.com
CVAC (CureVac NV) 9-Day RSI : 62.66 (As of Nov. 30, 2024) - GuruFocus.com
CVACCureVac N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Analysts Are Optimistic We'll See A Profit From CureVac N.V. (NASDAQ:CVAC) - Simply Wall St
CureVac NV (STU:5CV) Total Assets : €854.2 Mil (As of Sep. 2024) - GuruFocus.com
CVAC (CureVac NV) Capex-to-Operating-Cash-Flow : 0.01 (As of Sep. 2024) - GuruFocus.com
Loss-Making CureVac N.V. (NASDAQ:CVAC) Set To Breakeven - Yahoo Finance
Is the Options Market Predicting a Spike in CureVac (CVAC) Stock? - MSN
CureVac NV (STU:5CV) Total Inventories : €0.5 Mil (As of Sep. 2024) - GuruFocus.com
CureVac NV (STU:5CV) 50-Day SMA : €2.65 (As of Nov. 21, 2024) - GuruFocus.com
CureVac NV (XTER:5CV) Float Percentage Of Total Shares Outs - GuruFocus.com
CureVac NV (STU:5CV) Retained Earnings : €-1,371.0 Mil (As of Sep. 2024) - GuruFocus.com
CureVac NV (FRA:5CV) Retained Earnings : €-1,371.0 Mil (As of Sep. 2024) - GuruFocus.com
CureVac NV (FRA:5CV) Free Cash Flow : €94.5 Mil (TTM As of Sep. 2024) - GuruFocus.com
CureVac NV (HAM:5CV) 3-Year Revenue Growth Rate : -16.20% (As of Sep. 2024) - GuruFocus.com
CureVac NV (FRA:5CV) EBITDA : €165.9 Mil (TTM As of Sep. 2024) - GuruFocus.com
CureVac’s stock soars on GSK’s $1.56 billion deal for its COVID-19 and flu vaccines - MSN
10 Best German Stocks To Buy Now - Insider Monkey
Is CureVac N.V. (CVAC) the Best German Stock to Buy Now? - Insider Monkey
CureVac NV (HAM:5CV) 3-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com
CVAC (CureVac NV) Short-Term Capital Lease Obligation : $5.46 Mil (As of Jun. 2024) - GuruFocus.com
mRNA Vaccine and Therapeutics Market 2024-2031: Global - openPR
CureVac NV earnings beat by €0.09, revenue topped estimates - Investing.com Canada
CureVac N.V. (NASDAQ:CVAC) Q3 2024 Earnings Call Transcript - Insider Monkey
CureVac NV (CVAC) Q3 2024 Earnings Call Highlights: Strong Financial Performance and Strategic ... - Yahoo Finance
CureVac Reports Significant Revenue Growth Amid Strategic Restructuring - TipRanks
CureVac Reports Surging Revenues and Profit Growth - TipRanks
CureVac on track with 30% workforce reduction - TipRanks
CureVac reports Q3 revenue EUR 493.9M vs. EUR 16.5M last year - TipRanks
CureVac sees cash runway into 2028 - TipRanks
CureVac Announces Financial Results for the Third Quarter and Fi - WICZ
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update - AccessWire
큐어백 (CVAC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):